Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy

AIMS: Sacubitril/valsartan (SAC/VAL) has been used in patients with heart failure and reduced ejection fraction (HFrEF), and cardiac resynchronization therapy (CRT) could benefit the HFrEF patients with wide QRS durations. This study aimed to evaluate the clinical impacts of SAC/VAL on reverse cardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hsin‐Ti, Huang, Jin‐Long, Lin, Po‐Lin, Lee, Ying‐Hsiang, Hsu, Chien‐Yi, Chung, Fa‐Po, Liao, Chia‐Te, Chiou, Wei‐Ru, Lin, Wen‐Yu, Liang, Huai‐Wen, Chang, Hung‐Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773776/
https://www.ncbi.nlm.nih.gov/pubmed/35945811
http://dx.doi.org/10.1002/ehf2.14107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773776/
https://www.ncbi.nlm.nih.gov/pubmed/35945811
http://dx.doi.org/10.1002/ehf2.14107

Ejemplares similares